Basic Information
Cinryze
Regulatory Information
EMEA/H/C/001207
June 15, 2011
March 17, 2011
24
September 26, 2024
Company Information
Austria
Industriestrasse 67 1221 Vienna
Takeda Manufacturing Austria AG
Drug Classification
Active Substances Detail
EMA Resources
Detailed Information
Therapeutic Indication
### Therapeutic indication Treatment and pre-procedure prevention of angioedema attacks in adults, adolescents and children (2 years old and above) with hereditary angioedema (HAE). Routine prevention of angioedema attacks in adults, adolescents and children (6 years old and above) with severe and recurrent attacks of hereditary angioedema (HAE), who are intolerant to or insufficiently protected by oral prevention treatments, or patients who are inadequately managed with repeated acute treatment.
Overview Summary
This is a summary of the European public assessment report (EPAR) for Cinryze. It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Cinryze.